- Home
- ARQT
as 05-08-2025 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 1.6B | IPO Year: | 2020 |
| Target Price: | $18.80 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.99 - $17.75 | Next Earning Date: | 05-06-2025 |
| Revenue: | $212,819,000 | Revenue Growth: | 100.03% |
| Revenue Growth (this year): | 57.99% | Revenue Growth (next year): | 41.24% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Matsuda Masaru | ARQT | See Remarks | May 2 '25 | Sell | $15.20 | 5,030 | $76,453.49 | 204,399 | |
| Watanabe Todd Franklin | ARQT | See Remarks | May 2 '25 | Sell | $15.19 | 11,448 | $173,916.87 | 913,795 | |
| Welgus Howard G. | ARQT | Director | May 1 '25 | Sell | $14.64 | 10,000 | $146,357.00 | 111,944 | |
| Topper David Joseph | ARQT | Chief Financial Officer | Apr 2 '25 | Sell | $15.80 | 9,600 | $151,698.24 | 182,774 | |
| Welgus Howard G. | ARQT | Director | Apr 1 '25 | Sell | $15.12 | 10,000 | $151,236.00 | 111,944 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Mar 24 '25 | Sell | $17.54 | 3,671 | $64,413.39 | 913,795 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Mar 17 '25 | Sell | $17.61 | 1,200 | $21,137.04 | 913,795 | |
| Burnett Patrick | ARQT | See Remarks | Mar 13 '25 | Sell | $15.04 | 61,403 | $920,510.48 | 121,936 | |
| Welgus Howard G. | ARQT | Director | Mar 3 '25 | Sell | $13.00 | 10,000 | $130,048.00 | 111,944 | |
| Matsuda Masaru | ARQT | See Remarks | Feb 28 '25 | Sell | $13.03 | 3,263 | $42,520.48 | 204,399 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 hours ago
Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations
Thomson Reuters StreetEvents
a day ago
Q1 2025 Arcutis Biotherapeutics Inc Earnings Call
GlobeNewswire
a day ago
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
GuruFocus.com
2 days ago
Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...
Zacks
2 days ago
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
2 days ago
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Simply Wall St.
2 days ago
Exploring High Growth Tech Stocks In The US Market
GuruFocus.com
3 days ago
What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.